Despite chatter on the Street Wednesday afternoon, the principals weren't talking after Reuters and other news outlets reported that Amgen Inc. sweetened its offer for Onyx Pharmaceuticals Inc. to $130 per share, up from $120 per share in the unsolicited bid in late June.